Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACTION: etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
2014-003090-42Phase 2Unknown
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of pembrolizumab in small cell lung cancer (SCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-Free Survival. Status: unknown.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2014-003090-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003090-42.